Long-term follow-up for wet AMD treatment
Part of Eyes & vision clinical trials.
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken the study drug EXG102-031 before in an earlier study (called EXG102-031-111).
- You must be willing to sign a consent form and follow the study's rules.
- You must be able to commit to long-term check-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called EXG202 for wet age-related macular degeneration, a common cause of vision loss. The goal is to see if a single treatment can safely reduce the need for frequent eye injections.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.